Bettapharma
Bettapharma mainly providing customers with products such as Ectinib hydrochlorid
Beda Pharmaceuticals is an innovative drug developer in the fields of malignancy, ophthalmology, autoimmune diseases and diabetes, mainly providing customers with products such as Ectinib hydrochloride (Kemena), new antineoplastic drug CM082 and other products, including six national Class I and Class II new drugs, and 14 national Class III and Class IV new drugs in the pipeline.
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Boten Co., Ltd.: direnavir API has passed who PQ certification
TECO shares: obtained an invention patent certificate
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
The first bank of China fund to release its second Quarterly Report
Beida pharmaceutical: the three shareholders intend to reduce the shares of the company no more than 2.31%